Covid after Moderna booster; Interchange of vaccine products; Revaccination with different COVID-19 vaccine; This spontaneous case was reported by a pharmacist and describes the occurrence of COVID-19 (Covid after Moderna booster), INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products) and COVID-19 IMMUNISATION (Revaccination with different COVID-19 vaccine) in a 62-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis.     Previously administered products included for Product used for unknown indication: Pfizer (Dose 1) in March 2021 and Pfizer (Dose 2) in May 2021. Past adverse reactions to the above products included No adverse event with Pfizer and Pfizer.    In December 2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In December 2021, the patient experienced INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products) and COVID-19 IMMUNISATION (Revaccination with different COVID-19 vaccine). On 23-Aug-2022, the patient experienced COVID-19 (Covid after Moderna booster). The patient was treated with NIRMATRELVIR, RITONAVIR (PAXLOVID) for COVID-19 treatment, at an unspecified dose and frequency. At the time of the report, COVID-19 (Covid after Moderna booster), INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products) and COVID-19 IMMUNISATION (Revaccination with different COVID-19 vaccine) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 23-Aug-2022, SARS-CoV-2 test: (Positive) Positive.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant medication was not reported.  Company comment: This is a spontaneous case concerning a 62-year-old female patient with no medical history reported, who experienced the non-serious, unexpected AESI event of COVID-19, which occurred on an unknown date eight months after the third dose of mRNA-1273 of the COVID-19 schedule of vaccination, previously vaccinated with two doses of Pfizer COVID-19 vaccine. Interchange of vaccine products and Revaccination with different COVID-19 vaccine were considered as additional events. It was reported that the patient experienced COVID-19 after Moderna booster and was treated with Nirmatrelvir, Ritonavir (PAXLOVID). The outcome of the event was unknown at the time of the last observation. No further clinical information was provided for review. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.; Sender's Comments: This is a spontaneous case concerning a 62-year-old female patient with no medical history reported, who experienced the non-serious, unexpected AESI event of COVID-19, which occurred on an unknown date eight months after the third dose of mRNA-1273 of the COVID-19 schedule of vaccination, previously vaccinated with two doses of Pfizer COVID-19 vaccine. Interchange of vaccine products and Revaccination with different COVID-19 vaccine were considered as additional events. It was reported that the patient experienced COVID-19 after Moderna booster and was treated with Nirmatrelvir, Ritonavir (PAXLOVID). The outcome of the event was unknown at the time of the last observation. No further clinical information was provided for review. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.